Revolution Medicines Inc.

NAS: RVMD

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Revolution Medicines Inc.

Market open

--Real time quotes

Jun 6, 2023, 12:27 p.m.

RVMD

/zigman2/quotes/216320743/composite

26.73

Change

+0.91 +3.51%

Volume

Volume 320,662

Real time quotes

/zigman2/quotes/216320743/composite

Previous close

$ 25.82

$ 26.73

Change

+0.91 +3.51%

Day low

Day high

$25.75

$27.00

52 week low

52 week high

$15.64

$31.37

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Revolution Medicines Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	20.17M	50.04M	42.98M	29.39M	35.38M
Sales Growth	-	148.16%	-14.10%	-31.62%	20.38%
Cost of Goods Sold (COGS) incl. D&A	1.76M	-	-	7.33M	9.66M
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	1.76M	3.34M	6.55M	7.33M	9.66M
Depreciation	1.57M	2.27M	5.48M	6.26M	8.59M
Amortization of Intangibles	198,000	1.07M	1.07M	1.07M	1.07M
COGS Growth	-	-	-	-	31.70%
Gross Income	18.4M	-	-	22.06M	25.72M
Gross Income Growth	-	-	-	-	16.62%
Gross Profit Margin	-	-	-	-	72.71%	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	58.33M	100.22M	147.14M	210.07M	284M
Research & Development	51.08M	91.16M	128.57M	182.8M	248.03M
Other SG&A	7.25M	9.06M	18.56M	27.27M	35.97M
SGA Growth	-	71.82%	46.81%	42.77%	35.20%
Other Operating Expense	-	-	-	-	-
Unusual Expense	2.52M	-	-	-	-
EBIT after Unusual Expense	(42.45M)	-	-	-	-
Non Operating Income/Expense	-	(597,000)	-	-	-
Non-Operating Interest Income	777,000	2.19M	2.24M	929,000	9.15M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	116,000	106,000	71,000	12,000	-
Interest Expense Growth	-	-8.62%	-33.02%	-83.10%	-
Gross Interest Expense	116,000	106,000	71,000	12,000	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(41.79M)	(52.04M)	(108.53M)	(187.09M)	(249.13M)
Pretax Income Growth	-	-24.52%	-108.56%	-72.39%	-33.16%
Pretax Margin	-	-	-	-	-704.14%	NA
Income Tax	-	(4.37M)	(371,000)	-	(420,000)
Income Tax - Current Domestic	-	(4.37M)	(371,000)	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(41.79M)	(47.66M)	(108.16M)	(187.09M)	(248.71M)
Minority Interest Expense	-	-	-	-	-
Net Income	(41.79M)	(47.66M)	(108.16M)	(187.09M)	(248.71M)
Net Income Growth	-	-14.06%	-126.92%	-72.98%	-32.93%
Net Margin Growth	-	-	-	-	-702.95%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(41.79M)	(47.66M)	(108.16M)	(187.09M)	(248.71M)
Preferred Dividends	7.03M	14.24M	2.22M	-	-
Net Income Available to Common	(48.82M)	(61.9M)	(110.38M)	(187.09M)	(248.71M)
EPS (Basic)	(0.83)	(1.05)	(1.66)	(2.57)	(3.08)
EPS (Basic) Growth	-	-26.81%	-57.96%	-55.05%	-20.04%
Basic Shares Outstanding	59M	59M	66.6M	72.81M	80.63M
EPS (Diluted)	(0.83)	(1.05)	(1.66)	(2.57)	(3.08)
EPS (Diluted) Growth	-	-26.81%	-57.96%	-55.05%	-20.04%
Diluted Shares Outstanding	59M	59M	66.6M	72.81M	80.63M
EBITDA	(38.17M)	(50.18M)	(104.15M)	(180.68M)	(248.62M)
EBITDA Growth	-	-31.48%	-107.55%	-73.47%	-37.61%
EBITDA Margin	-	-	-	-	-702.72%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Revolution Medicines Inc.

Annual Financials for Revolution Medicines Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk